<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01981499</url>
  </required_header>
  <id_info>
    <org_study_id>B3441009</org_study_id>
    <nct_id>NCT01981499</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults</brief_title>
  <official_title>A Phase 1, Placebo-Controlled, Crossover, Subject- And Investigator-Blind, Sponsor-Open Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of A Modified-Release Formulation Of PF-05180999 In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PF-05180999 is a phosphodiesterase-2 inhibitor that is hypothesized to be able to reduce
      vascular permeability. The purpose of this study is to evaluate the safety, tolerability,
      pharmacokinetics, and effects on histamine-induced wheal of single doses of PF-05180999 in
      healthy adult subjects. Histamine-induced wheals are biomarkers of vascular permeability.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was prematurely terminated on 01April2014 due to safety concerns.
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0-72 hours post-dose</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0-72 hours post-dose</time_frame>
    <description>Time when Cmax occurred</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>0-72 hours post-dose</time_frame>
    <description>Measure of drug absorption and drug exposure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf)</measure>
    <time_frame>0-infinity hours post-dose</time_frame>
    <description>Measure of drug absorption and drug exposure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Half-Life (t1/2)</measure>
    <time_frame>0-72 hours post-dose</time_frame>
    <description>Time for the plasma concentration to decrease by one-half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Effect Curve (AUEC) for Histamine-Induced Wheal</measure>
    <time_frame>2-12 hours post-dose</time_frame>
    <description>Measure of drug effect</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-response, exposure-response, and maximum response for PF-05180999 against histamine-induced wheal</measure>
    <time_frame>0-72 hours post-dose</time_frame>
    <description>Measures of drug effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Effect Curve (AUEC) for histamine-induced flare; Dose-response, exposure-response, and maximum response for PF-05180999 against histamine-induced flare</measure>
    <time_frame>0-72 hours post-dose</time_frame>
    <description>Measures of drug effect</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Arm A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999 relative to placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B of study to assess effects of PF-05180999 on histamine-induced wheal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B of study to assess effects of PF-05180999 on histamine-induced wheal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Positive control to ensure histamine-induced wheal assay integrity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05180999</intervention_name>
    <description>Ascending single oral doses of 120, 240, and 420 mg modified-release tablets</description>
    <arm_group_label>Arm A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets</description>
    <arm_group_label>Arm A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>120 mg MR PF-05180999</intervention_name>
    <description>Single 120 mg dose administered as modified release formulation</description>
    <arm_group_label>Arm B1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>360 mg MR PF-05180999</intervention_name>
    <description>Single 360 mg dose administered as modified release formulation</description>
    <arm_group_label>Arm B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg cetirizine</intervention_name>
    <description>Single 10 mg dose of cetirizine</description>
    <arm_group_label>Arm B3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets</description>
    <arm_group_label>Arm B4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 18 and 55 years

          -  No history of clinically-relevant atopic or dermatological disease

          -  Positive reaction to intradermal injection of histamine

        Exclusion Criteria:

          -  Subjects with screening laboratory test results that deviate from the upper and/or
             lower limits of the reference or acceptable range. The exception is that all liver
             function tests must not exceed the upper limit of normal.

          -  Subjects with evidence of, or history of, hepatic disorder, including acute or chronic
             hepatitis B or hepatitis C

          -  Intolerance to intradermal histamine injection.

          -  Subjects with dark skin (Part B only).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3441009&amp;StudyName=A%20Study%20of%20the%20Safety%2C%20Tolerability%2C%20Pharmacokinetics%2C%20And%20Effects%20On%20Histamine-Induced%20Wheal%20Of%20PF-05180999%20In%20Healthy%20Adults%20%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2013</study_first_submitted>
  <study_first_submitted_qc>November 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2013</study_first_posted>
  <last_update_submitted>May 6, 2014</last_update_submitted>
  <last_update_submitted_qc>May 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PF-05180999</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>histamine</keyword>
  <keyword>wheal</keyword>
  <keyword>flare</keyword>
  <keyword>migraine</keyword>
  <keyword>PDE2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Histamine phosphate</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

